Abstract
Mutations in the dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS) genes of Plasmodium falciparum have been correlated with and used to detect antifolate treatment failure, such as sulfadoxine–pyrimethamine (SP), in regions endemic for malaria. To determine the association between molecular markers of SP resistance and in vivo drug resistance, a quick and simple technique that detects single nucleotide polymorphisms in the DHFR and DHPS genes, using PCR–ELISA and sequence-specific oligonucleotide probes, was applied to 53 isolates obtained from an in vivo study in Sistan and Baluchistan Province, in southeastern Iran. Overall, 11.3% of these isolates were obtained from patients with SP treatment failure. Four DHFR polymorphisms (codons 51, 59, 108, and 164) and five DHPS polymorphisms (codons 436, 437, 540, 581, and 613) were investigated. Mutations DHFR Asn-108, DHFR Arg-59, and DHPS 436-Ala/Phe were very common (100, 81.1, and 85%, respectively). Plasmodium falciparum was isolated from 96% of patients with at least two DHFR/DHPS mutations. All resistant isolates had at least three mutations. The high prevalence of mutation associated with antifolate resistance may point toward low drug efficacy in the future.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abdel-Hameed AA (2003) Antimalarial drug resistance in the Eastern Mediterranean region. East Mediterr Health J 9(4):492–508
Alifrangis M, Enosse S (2005) A simple, high throughput method to detect Plasmodium falciparum single nucleotide polymorphisms in the dihydrofolate reductase, dihydropteroate syntase, and P. falciparum Chloroquine resistance transporter genes using polymerase chain reaction and Enzyme-linked immunosorbent Assay-based technology. Am J Trop Med Hyg 72(2):155–162
Berens N, Schwoebel B (2003) Plasmodium falciparum: correlation of in vivo resistance to chloroquine and antifolates with genetic polymorphisms in isolates from the south of Lao PDR. Trop Med Int Health 8(9):775–782
Berzosa PJ, Puente S (2005) Malaria cure with sulphadoxine/pyrimethamine combination in 12 semi-immune adults from West-central Africa with high rates of point mutation in Plasmodium falciparum dhfr and dhps genes. Parasitol Res 97(4):287–289
Brooks DR, Wang P (1994) Sequence variation of the hydroxy-methyldihydropterin pyrophosphokinase: dihydopteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur J Biochem 224(2):397–405
Edrissian GH (1989) Status of the response of Plasmodium falciparum to Chloroquine in Iran. Trop Geogr Med 41(4):297–303
Edrissian GH, Afshar A (1993) Assessment of the response in vivo and in vitro of Plasmodium falciparum to sulphadoxine–pyrimethamine in the malarious areas of Iran. J Trop Med Hyg 96(4):237–240
Eskandarian AA, Keshavarz H (2002) Do mutations in Plasmodium falciparum dihydropteroate synthase and dihydrofolate reductase confer resistance to sulfadoxine–pyrimethamine in Iran? Trans R Soc Trop Med Hyg 96(1):96–98
Happi CT, Gbotosho GO (2005) Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine–pyrimethamine resistance in malaria-infected patients from Nigeria. Acta Trop 95(3):183–193
Jelinek T, Ronn AM (1998) Polymorphisms in the dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS) genes of Plasmodium falciparum and in vivo resistance to sulphadoxine/pyrimethamine in isolates from Tanzania. Trop Med Int Health 3(8):605–608
Khan MA, Smego RA (2004) Emerging drug-resistance and guidelines for treatment of malaria. J Coll Physicians Surg Pak 14(5):319–324
Kublin JG, Witzig RS (1998) Molecular assays for surveillance of antifolate-resistance malaria. Lancet 351:1629–1630
Rakhsani F, AnsariMoghadam AR (2003) Knowledge, perceptions and prevention of malaria among women in Sistan va Baluchestan, Islamic Republic of Iran. East Mediterr Health J 9(3):248–256
WHO (2005) The work of WHO in the Eastern Mediterranean region. Annual report of regional director. WHO Regional Office for the Eastern Mediterranean, Alexandria
WHO–CDS/RBM (2002) Monitoring antimalarial drug resistance—report of a WHO consultation, vol 39. WHO, Geneva
Zakeri S, Gil JP (2003) High prevalence of double Plasmodium falciparum dhfr mutation at codons 108 and 59 in the Sistan–Baluchistan province, Iran. J Infect Dis 187(11):1828–1829
Acknowledgements
We would like to thank those patients who kindly contributed to this study. We are grateful to Mr. Satvat, Mr. Akbarzadeh, and Mr. Seidzadeh for their assistance in sampling; Dr. Edrissian; Dr. Farhood; and all the staff of the Institute of Tropical Medicine of Berlin. This study was supported financially by the Iranian Ministry of Health and the Institute of Tropical Medicine in Berlin, Germany.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Heidari, A., Dittrich, S., Jelinek, T. et al. Genotypes and in vivo resistance of Plasmodium falciparum isolates in an endemic region of Iran. Parasitol Res 100, 589–592 (2007). https://doi.org/10.1007/s00436-006-0291-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00436-006-0291-z